NET-7 inhibitors represent a category of chemical agents specifically designed to suppress the activity of NET-7, a fictional enzyme involved in critical cellular processes. These inhibitors are developed with the intention of directly interacting with the NET-7 protein, leading to a decrease in its enzymatic activity. By targeting NET-7, these chemicals can influence the cellular pathways and processes regulated by this enzyme, potentially affecting the overall cellular homeostasis and function. The inhibition of NET-7 involves the binding of these chemicals to the active site or allosteric sites of the enzyme, thereby blocking its interaction with substrates or cofactors essential for its activity. This blockade can result in the modulation of the cellular signaling pathways and biological processes in which NET-7 plays a pivotal role. The development of NET-7 inhibitors is guided by a deep understanding of the enzyme's structure, the biochemical pathways it influences, and the role it plays in cellular physiology.
The research and development process for NET-7 inhibitors encompasses a series of methodological approaches, including computational modeling to predict the interaction between potential inhibitors and the NET-7 protein, biochemical assays to confirm these interactions and measure their impact on enzyme activity, and cellular assays to observe the downstream effects on cellular functions. Techniques such as molecular docking and dynamic simulation are employed to identify molecules with high binding affinity for NET-7, while kinetic studies provide insights into how these interactions affect the enzyme's function. Further, the use of cell-based assays helps in understanding the physiological relevance of NET-7 inhibition, including changes in cellular signaling pathways, alterations in gene expression, and impacts on cell proliferation, differentiation, or apoptosis. Through these comprehensive research strategies, scientists aim to elucidate the mechanisms by which NET-7 inhibitors exert their effects, providing valuable insights into the role of NET-7 in cellular processes and the potential for modulating its activity for investigative purposes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 280264X | 866924-39-2 | sc-507540 | 5 mg | $720.00 | ||
GW280264X inhibits ADAM10, a protease regulated by NET-7, thereby disrupting NET-7's ability to facilitate ADAM10's maturation and trafficking. | ||||||
GI 254023X | 260264-93-5 | sc-490114 | 1 mg | $166.00 | 1 | |
GI 254023X targets ADAM10 and interrupts NET-7's regulatory role in CDH2 cleavage and Notch signaling by impeding ADAM10 activity. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat inhibits metalloproteases, including ADAM10, thereby affecting NET-7's function in the maturation and trafficking of ADAM10. | ||||||
TAPI-1 | 171235-71-5 | sc-222337 | 1 mg | $669.00 | 15 | |
TAPI-1 directly inhibits the activity of ADAM10, which is regulated by NET-7, thus impacting NET-7’s ability to regulate CDH2 cleavage. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat acts as an ADAM10 inhibitor and disrupts NET-7's role in ADAM10 maturation and trafficking. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT inhibits gamma-secretase and can reduce Notch signaling, which NET-7 negatively regulates, thus affecting NET-7's role in Notch pathway regulation. | ||||||
LY411575 | 209984-57-6 | sc-364529 sc-364529A | 10 mg 50 mg | $198.00 $473.00 | 6 | |
LY411575 inhibits gamma-secretase, reducing Notch signaling, and in doing so, indirectly affects NET-7's role in regulating this pathway. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
RO-4929097 acts as a gamma-secretase inhibitor, affecting Notch signaling and, by extension, NET-7's regulatory role in this pathway. | ||||||
Dibenzazepine (Deshydroxy LY 411575) | 209984-56-5 | sc-207554 sc-207554A | 2 mg 5 mg | $235.00 $260.00 | 4 | |
Dibenzazepine (Deshydroxy LY 411575) is a gamma-secretase inhibitor that affects Notch signaling, thereby affecting NET-7's ability to regulate this pathway. | ||||||
L-685,458 | 292632-98-5 | sc-204042 sc-204042A | 1 mg 5 mg | $337.00 $1000.00 | 4 | |
L-685,458 inhibits gamma-secretase, reducing Notch signaling, which is negatively regulated by NET-7. | ||||||